Frontlight ResearchEarly access
CompletedPhase 3
Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients
Key facts
- Who runs it
- AO GENERIUM
- Where
- Russia13 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 160 people enrolled
- Started
- 28 Mar 2022
- Ended
- 3 Apr 2024
- Type of study
- Interventional
- Treatments tested
- GNR-069
- Record updated
- 21 June 2024
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (4)Hide the full registry criteria
Who can take part
- Completion of participation in the study RMP-ITP-III while maintaining the clinical effectiveness of romiplostim therapy
Who cannot take part
- Hypersensitivity to the components of the study drug or E. Coli proteins
- Any diseases and conditions that, in the opinion of the Investigator, may hinder the patient's participation in the study
- Pregnancy or breastfeeding
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
It is a phase III extension study to assess safety and immunogenicity of long-term therapy with GNR-069 in patients with idiopathic thrombocytopenic purpura
The group in the trial
- GNR-069Treatment being tested
Weekly subcutaneous injections of GNR-069 in the individually titrated dose.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Extension Study of Long-term Safety and Immunogenicity of GNR-069 Patients With Idiopathic Thrombocytopenic Purpura Who Completed Phase 3 RMP-ITP-III Clinical Trial
- Record updated
- 21 June 2024